PrescottJr, William A. Prescott; Doloresco, Fred; … - In: PharmacoEconomics 28 (2010) 4, pp. 279-293
immune globulin intravenous (RSV-IGIV) or palivizumab has been shown to be effective in reducing RSV-related hospitalizations …. Motavizumab, a new enhanced-potency humanized RSV monoclonal antibody, is presently in clinical trials. RSV-IGIV and palivizumab … cost effectiveness of palivizumab and five have analysed the cost effectiveness of both agents, two of which directly …